Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study

被引：0
|
作者：
Li Ying
Ji Suyun
Liang Yanhua
Liang Yunsheng
Deng Li
Dang Lin
Lv Chengzhi
Lin Bingjiang
Zhang Furen
Shi Wendi
Li Jinnan
Dong Yu
Dou Guanshen
Yuling Shi
机构：
[1] Tongji University School of Medicine,Department of Dermatology, Shanghai Skin Disease Hospital
[2] Southern Medical University,Department of Dermatology, Dermatology Hospital
[3] Southern Medical University,Department of Dermatology, Cosmetology and Venereology, Shenzhen Hospital
[4] Longgang Central Hospital of Shenzhen,Department of Dermatology
[5] Dalian Skin Disease Hospital,Department of Dermatology
[6] Ningbo First Hospital,Department of Dermatology
[7] Shandong First Medical University & Shandong Academy of Medical Sciences,Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology
[8] Eli Lilly and Company,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Efficacy; Ixekizumab; Psoriasis; Real world; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5464 / 5474
页数：10
相关论文
共 50 条
  • [21] Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferences
    Azhar, Aaminah
    Zaayman, Marcus
    Silfvast-Kaiser, Annika
    Kivelevitch, Dario
    Menter, Alan
    Paek, So Yeon
    DERMATOLOGIC THERAPY, 2021, 34 (01)
  • [22] Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
    Wayne Gulliver
    Melinda J. Gooderham
    Baojin Zhu
    Christian Jossart
    Sonia Montmayeur
    Russel Burge
    Catherine Reed
    Dermatology and Therapy, 2023, 13 : 235 - 244
  • [23] Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice
    Herrera-Acosta, Enrique
    Garriga-Martina, Gustavo G.
    Suarez-Perez, Jorge A.
    Martinez-Garcia, Eliseo A.
    Herrera-Ceballos, Enrique
    DERMATOLOGIC THERAPY, 2020, 33 (03)
  • [24] Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study
    Ying Li
    Chengzhi Lv
    Lin Dang
    Bingjiang Lin
    Juan Tao
    Chunlei Zhang
    Xiaoyong Zhou
    Han Ma
    Yi Lu
    Rong Chen
    Jinnan Li
    Guanshen Dou
    Yunsheng Liang
    Yanhua Liang
    Yuling Shi
    Dermatology and Therapy, 2024, 14 : 907 - 918
  • [25] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
    Blauvelt, Andrew
    Gooderham, Melinda
    Iversen, Lars
    Ball, Susan
    Zhang, Lu
    Agada, Noah O.
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (05) : 855 - 862
  • [26] Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
    Gaojie Li
    Yuanxia Gu
    Qin Zou
    Yiyi Wang
    Yue Xiao
    Dengmei Xia
    Tongying Zhan
    Xingli Zhou
    Qian Wang
    Wei Yan
    Wei Li
    Dermatology and Therapy, 2022, 12 : 2105 - 2115
  • [27] Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
    Li, Gaojie
    Gu, Yuanxia
    Zou, Qin
    Wang, Yiyi
    Xiao, Yue
    Xia, Dengmei
    Zhan, Tongying
    Zhou, Xingli
    Wang, Qian
    Yan, Wei
    Li, Wei
    DERMATOLOGY AND THERAPY, 2022, 12 (09) : 2105 - 2115
  • [28] Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
    Giunta, Alessandro
    Ventura, Alessandra
    Chimenti, Maria Sole
    Bianchi, Luca
    Esposito, Maria
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1643 - 1651
  • [29] Early onset of clinical improvement with ixekizumab in patients with moderate-to-severe plaque psoriasis
    Khatri, S.
    Amir, Y.
    Min, M.
    Goldblum, O.
    Solotkin, K.
    Yang, F.
    Ridenour, T.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 73 - 74
  • [30] Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab
    Gao, Xinghua
    Pan, Weili
    Zheng, Min
    Li, Fuqiu
    Dong, Xiuqin
    Lv, Dong
    Guo, Zaipei
    Li, Jinnan
    Wang, Xuan
    Geng, Songmei
    ADVANCES IN THERAPY, 2025, 42 (01) : 334 - 347
12345